spacer
home > ebr > spring 2002 > pharmacogenetics and the development of anticancer agents
PUBLICATIONS
European Biopharmaceutical Review

Pharmacogenetics and the Development of Anticancer Agents

The observation that individuals respond differently to the same drug is centuries old, yet only recently has the biological basis for such variation begun to be unravelled. In the field of pharmacogenetics, detailed biological understanding of the pathways by which drugs act and are metabolised, guides high throughput DNA sequencing efforts to reveal variations within genes critical to therapeutic response. Such variance data is used to associate responsiveness to a drug with specific genetic variations, which can then serve as predictive markers to guide drug usage. This article summarises progress in identifying genetic markers that predict the toxicity and efficacy of chemotherapeutic drugs. Several types of markers have been associated with response to a variety of anticancer agents, including DNA polymorphisms, loss of heterozygosity, and RNA expression patterns within tumours. Some genetic features of cancer that provide the basis for these markers are outlined briefly, examples of each type of marker are provided, and the utility of pharmacogenetics throughout the drug development process is discussed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ann E. Ferentz, Senior Scientist and Manager of Scientific Communications at Variagenics, Inc

Ann Ferentz obtained her BS from Yale University and her PhD in Chemistry from Harvard University. Her subsequent research at Harvard Medical School and the Massachusetts Institute of Technology focused on structural biology and cellular responses to DNA damage.
She is currently a Senior Scientist and Manager of Scientific Communications at Variagenics, a pharmacogenomics company in Cambridge, Massachusetts.

spacer
Ann E. Ferentz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera and Noble announce collaboration to support patients who self-administer medication

Nemera is excited to leverage the new collaboration to expand end-to- end offering of the parenteral franchise and increase patient onboarding through safer multi-use training devices
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement